Transcription Factor Reprogramming for cDC2 Generation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating conventional dendritic cells (cDCs), particularly cDC2s, face inefficiencies and complications in clinical settings due to reliance on autologous monocytes and hematopoietic progenitors, which are scarce and often compromised in cancer patients, leading to the production of dysfunctional DCs.
Innovation Solution
The use of specific combinations of transcription factors such as PU.1, IRF4, PRDM1, IRF2, RBPJ, RELB, POU2F2, and TGIF1 to reprogram differentiated or pluripotent stem cells into cDC2s, achieving phenotypic and functional characteristics of cDC2s, including surface marker expression and antigen presentation capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autologous monocytes and hematopoietic progenitors are used to generate cDCs, then the method relies on available patient cells, but the cells are scarce and often compromised in cancer patients, leading to dysfunctional DCs
Solution Approach 1:
The patent uses transcription factors (PU.1, IRF4, PRDM1, IRF2, RBPJ, RELB, POU2F2, TGIF1) as intermediaries to mediate the conversion of easily obtainable cells (fibroblasts, adipose-derived stem cells) into functional cDC2s. These transcription factors act as molecular mediators that reprogram the epigenetic and transcriptional network of donor cells to achieve cDC2 identity, bypassing the need for scarce hematopoietic progenitors
Solution Approach 2:
The patent fundamentally changes the starting material parameter from scarce autologous monocytes/hematopoietic progenitors to abundant easily obtainable cells (fibroblasts, adipose-derived stem cells). By combining this parameter change with transcription factor-mediated reprogramming, the method transforms cells with different baseline properties into functional cDC2s, resolving the contradiction between cell availability and functional reliability
2Productivity
If traditional differentiation methods are used from hematopoietic progenitors, then the process follows natural development, but the precursor cells are compromised in cancer patients resulting in low efficiency
Solution Approach 1:
Instead of following the natural bottom-up differentiation path from hematopoietic progenitors (which are compromised in cancer patients), the patent inverts the approach by using transcription factors to directly reprogram easily obtainable cells (fibroblasts, adipose-derived stem cells) into cDC2s. This top-down reprogramming strategy bypasses the compromised intermediate stages of natural hematopoiesis, achieving both high productivity and reliability
Solution Approach 2:
The patent applies preliminary action by pre-selecting and characterizing transcription factor combinations (PU.1, IRF4, PRDM1, IRF2, RBPJ, RELB, POU2F2, TGIF1) that are known to drive cDC2 differentiation. These pre-validated transcription factor cocktails are then applied to reprogram donor cells, ensuring efficient and reliable cDC2 generation without relying on the quality of patient-derived hematopoietic progenitors
Data Source
AI summary
The present disclosure relates to compositions for reprogramming cells into conventional dendritic cells (cDC), particularly into cDC type 2 (hereinafter referred to as“cDC2” or“CD11b-positive dendritic cells”), methods and uses thereof. The present disclosure relates to the development of methods for making conventional dendritic cells With antigen presenting capacity from differentiated, multipotent or pluripotent stem cells by introducing and expressing isolated/synthetic transcription factors. More particularly, the disclosure provides methods for obtaining conventional dendritic cells (cDC), particularly cDC type 2 or CD11b-positive dendritic cells, by direct cell reprogramming With the surprisingly use of combinations of specific transcription factors.